Cited by 264Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismPharmacovigilance and Adverse Drug Reactions

The DOI matches its Crossref record; 201 of the 205 references it cites were found in a registry or an index.

Statin Safety: An Overview and Assessment of the Data—2005

Bays, Harold·2006·The American Journal of Cardiology

DOI 10.1016/j.amjcard.2005.12.006

Open this paper in CoChat — free account

Abstract

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statin drugs, have been studied in numerous controlled human research trials involving hundreds of thousands of study participants. Statins have been prescribed for millions of patients. Based on this vast research and clinical experience, statins have been shown to improve lipid blood levels and reduce atherosclerotic coronary artery disease (CAD) risk, resulting in reduced CAD morbidity and mortality, and in several studies, reduced overall ("all-cause") mortality. From a safety perspective, both research trial evidence and clinical practice experience have demonstrated that statins are generally well tolerated. However, as with all pharmaceuticals, safety considerations exist with both monotherapy and combination statin therapy, mainly involving potential adverse effects on muscle, liver, kidney, and the nervous system. The evidence supporting statin-related potential adverse experiences on these organ systems is sometimes strong and based on clear clinical trial evidence (such as the increased risk of muscle enzyme elevation with higher statin doses). The evidence is at other times more speculative, being based on case reports and inconclusive clinical trial data (such as possible favorable or unfavorable effects of statins on cognition). Because the use of statins is so widespread, it is useful for the clinician to understand statin safety issues and the level of available evidence supporting the contention that various adverse effects are caused by statins. This review presents an assessment of statin safety based on an overview of the current statin safety data and their clinical implications.

Integrity signals

Registry

Crossref · 10.1016/j.amjcard.2005.12.006

Cites

201 of 201 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614

Flagged first, then by citations

Show all 205 references

4 of the 205 references couldn’t be matched to a known paper.

Research works printed but not linked: 9

Bottorff, 2004, Safety and statins, Am J Manag Care, 4, S27
2005, Position Statement, Diabetes Care, 28, S4
Bays, 2003, Colesevelam HCl, Expert Opin Pharmacother, 4, 779
Evans, 2004, Statin safety in perspective—maximising the risk:benefit, British Journal of Cardiology, 11, 449
Bays, 2003, Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]), Am J Cardiol, 91, 667, 10.1016/S0002-9149(03)00007-9 · DOI
Omar, 2002, FDA adverse event reports on statin-associated rhabdomyolysis, Ann Pharmacother, 36, 288, 10.1345/aph.1A289 · DOI · Paper page
Davidson, 2000, Lipid-altering efficacy and safety of simvastatin 80 mg/day, Nutr Metab Cardiovasc Dis, 10, 253
1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, Lancet, 344, 1383
Eckernas, 1993, The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep, Br J Clin Pharmacol, 35, 284

Sorted by citations

Items 101–200 of 262

Evaluation and discrimination of simvastatin-induced structural alterations in proteins of different rat tissues by FTIR spectroscopy and neural network analysis
Garip, Ş., Yapici, E., Özek, N. Ş., Severcan, M., & Severcan, F. (2010) · The Analyst · doi:10.1039/c0an00540a · Cited by 32
Safety of Niacin and Simvastatin Combination Therapy
Bays, H. E. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.026 · Cited by 32
Self-citation
Disorders of Lipid Metabolism
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00037-7 · Cited by 32
Clinical profile of statin intolerance in the phase 3 GAUSS-2 Study
Cho, L., Rocco, M., Colquhoun, D., Sullivan, D., Rosenson, R. S., Dent, R., Xue, A., Scott, R., Wasserman, S. M., & Stroes, E. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6655-4 · Cited by 30
Do the Frequencies of Adverse Events Increase, Decrease, or Stay the Same with Long-Term Use of Statins?
Huddy, K., Dhesi, P., & Thompson, P. D. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0301-9 · Cited by 30
What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
Bays, H. E., & Ballantyne, C. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283325083 · Cited by 29
Self-citation
Statin associated muscle symptoms: An update and review
Dicken, W., Mehta, A., Karagiannis, A. D., Jain, V., Vavuranakis, M., Sperling, L. S., & Cassimatis, D. C. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.010 · Cited by 30
Statin-induced myopathy in a usual care setting—a prospective observational study of gender differences
Skilving, I., Eriksson, M., Rane, A., & Ovesjö, M.-L. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2105-2 · Cited by 28
Cholesterol intake and statin use regulate neuronal G protein-gated inwardly rectifying potassium channels
Bukiya, A. N., Blank, P. S., & Rosenhouse‐Dantsker, A. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m081240 · Cited by 28
Drugs Causing Muscle Disease
Mor, A., Wortmann, R. L., Mitnick, H. J., & Pillinger, M. H. (2011) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2011.01.005 · Cited by 28
Disorders of Peripheral Nerves
Katirji, B., & Koontz, D. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0434-1.00101-8 · Cited by 28
Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia
Abbas, A., Milles, J. J., & Ramachandran, S. (2012) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s7591 · Cited by 28
Intracellular cholesterol accumulation and coenzyme Q10 deficiency in Familial Hypercholesterolemia
Suarez-Rivero, J. M., de la Mata, M., Pavón, A. D., Paz, M. V., Povea-Cabello, S., Cotán, D., Álvarez-Córdoba, M., Villalón-García, I., Ybot‐González, P., Salas, J. J., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.009 · Cited by 27
Effect of SLCO1B1 T521C on Statin‐Related Myotoxicity With Use of Lovastatin and Atorvastatin
Lu, B. D., Sun, L., Seraydarian, M., Hoffmann, T. J., Medina, M. W., RISCH, N. J., Iribarren, C., Krauss, R. M., & Oni‐Orisan, A. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2337 · Cited by 26
Prevalence and clinical significance of liver function abnormalities in patients with acute heart failure
Vyskočilová, K., Špinarová, L., Špinar, J., Mikušová, T., Vítovec, J., Malek, J., Málek, F., Linhart, A., Fedorco, M., Widimský, P., et al. (2014) · Biomedical Papers · doi:10.5507/bp.2014.014 · Cited by 26
Inhibition of foam cell formation using a soluble CD68-Fc fusion protein
Daub, K., Siegel-Axel, D. I., Schönberger, T., Leder, C., Seizer, P., Müller, K., Schaller, M., Penz, S. M., Menzel, D., Büchele, B., et al. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0629-y · Cited by 25
mTORC2 is an important target for simvastatin-associated toxicity in C2C12 cells and mouse skeletal muscle – Roles of Rap1 geranylgeranylation and mitochondrial dysfunction
Sanvee, G. M., Hitzfeld, L., Bouitbir, J., & Krähenbühl, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114750 · Cited by 25
Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: Synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator
Lapchak, P. A., & Han, M. (2010) · Brain Research · doi:10.1016/j.brainres.2010.05.035 · Cited by 24
Drug therapy for chronic idiopathic axonal polyneuropathy
Warendorf, J. K., Vrancken, A. F. J. E., van Schaik, I. N., Hughes, R. A., & Notermans, N. C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003456.pub3 · Cited by 23
Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors.
Bays, H. E., & Jones, P. H. (2007) · PubMed Central · Cited by 24
Self-citation
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits
Lapchak, P. A., & Han, M. (2009) · Brain Research · doi:10.1016/j.brainres.2009.09.064 · Cited by 24
Hydroxypropylmethylcellulose lowers cholesterol in statin-treated men and women with primary hypercholesterolemia
Maki, K. C., Carson, M. L., Miller, M. P., Anderson, W. H. K., Turowski, M., Reeves, M. S., Kaden, V. N., & Dicklin, M. R. (2009) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2009.9 · Cited by 23
Spruce Needle Polyprenols Protect Against Atorvastatin-Induced Muscle Weakness and do not Influence Central Nervous System Functions in Rats
Jansone, B., Dzirkale, Z., Jekabsons, K., Pilipenko, V., Beitnere, U., Māgure, I., Skumbiņš, R., Klētnieks, U., Vanaga, I., Muceniece, R., et al. (2016) · Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. · doi:10.1515/prolas-2016-0003 · Cited by 23
Statin-induced rhabdomyolysis in patient with renal failure and underlying undiagnosed hypothyroidism
Ambapkar, S. N., Shetty, N., Dwivedy, A., & Malve, H. (2016) · Indian Journal of Critical Care Medicine · doi:10.4103/0972-5229.182210 · Cited by 23
Statin Myopathy: A Lipid Clinic Experience on the Tolerability of Statin Rechallenge
Fung, E. C., & Crook, M. A. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2011.00267.x · Cited by 34
Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors
Roy, S., Weinstock, J. L., Ishino, A. S., Benites, J., Pop, S. R., Perez, C., Gumbs, E. A., Rosenbaum, J. A., Roccato, M. K., Shah, H., et al. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3066w · Cited by 23
Treatment of Dyslipidemia and Cardiovascular Outcomes: The Journey So Far—Is This the End for Statins?
Zoungas, S., Curtis, A. J., McNeil, J. J., & Tonkin, A. M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.86 · Cited by 22
Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction amino acid sequence of the translocator protein TSPO
Lecanu, L., Yao, Z., McCourty, A., Sidahmed, E., Orellana, M. E., Burnier, M. N., & Papadopoulos, V. (2012) · Steroids · doi:10.1016/j.steroids.2012.10.018 · Cited by 21
Beneficial Effects of Hydroalcoholic Extract from Rosa Roxburghii Tratt Fruit on Hyperlipidemia in High-Fat-Fed Rats.
Wu, P.-H., Han, S. C.-H., & Wu, M.-H. (2020) · PubMed Central · doi:10.6515/acs.202003_36(2).20190709a · Cited by 21
Statin-related Muscle Toxicity: An Evidence-based Review
Jeeyavudeen, M. S., Pappachan, J. M., & Arunagirinathan, G. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.89 · Cited by 21
Statins and stroke prevention
Paciaroni, M., & Bogousslavsky, J. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.106 · Cited by 21
Statins and amyotrophic lateral sclerosis – the level of evidence for an association
Sørensen, H. T., & Lash, T. L. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02173.x · Cited by 21
Advances in the management of hyperlipidemia-induced atherosclerosis
Tannock, L. R. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.369 · Cited by 21
Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: A 12-week, multicenter, randomized, open-label, parallel-group study
Alvarez-Sala, L. A., Cachofeiro, V., Masana, L., Suárez, C., Pinilla, B., Plana, N., Trias, F., Moreno, M. Á., Gambús, G., Lahera, V., et al. (2008) · Clinical Therapeutics · doi:10.1016/j.linthera.2008.01.013 · Cited by 20
Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism
Zhao, M., Wang, S., Jiang, Y., Wang, Y., Shen, H., Xu, P., Xiang, H., & Xiao, H. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0472-z · Cited by 19
Statin-Associated Myopathy in a Pediatric Preventive Cardiology Practice
Johnson, P. K., Mendelson, M., Baker, A., Ryan, H. H., Warren, S., Graham, D. A., Griggs, S., Desai, N. K., Yellen, E., Buckley, L. P., et al. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.02.047 · Cited by 19
Non-every day statin administration — A literature review
Elis, A., & Lishner, M. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.02.006 · Cited by 18
A Current Approach to Statin Intolerance
Tompkins, R. O., Schwartzbard, A. Z., Gianos, E., Fisher, E. A. A., & WEINTRAUB, H. S. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.84 · Cited by 17
Analysis and comparison of statin prescription patterns and outcomes according to clinical department
Kim, H., Kim, H.-E., Lee, H., Park, B. H., Park, S. S., Lee, S., Cho, J. H., Song, H., Kim, J. H., Yoon, K., et al. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12350 · Cited by 17
Longitudinal trends and predictors of statin use among patients with diabetes
Brennan, M. B., Huang, E. S., Lobo, J. M., Kang, H., Guihan, M., Basu, A., & Sohn, M. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.09.014 · Cited by 17
Rhabdomyolysis induced acute renal failure secondary to statins
Ram, R., Swarnalatha, G., Ramesh, V., Rao, K., & Dakshinamurty, K. (2013) · Indian Journal of Nephrology · doi:10.4103/0971-4065.111853 · Cited by 17
Cost-Effectiveness of Rosuvastatin in the Prevention of Ischemic Heart Disease in Portugal
Pinto, C. G., Carrageta, M., & Miguel, L. S. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00224.x · Cited by 17
The effects of simvastatin on angiogenesis: studied by an original model of atherosclerosis and acute myocardial infarction in rabbit
Shen, W., Shi, H., Wei-hu, F., Luo, X.-P., Jin, B., & Li, Y. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0497-0 · Cited by 16
The Risk for Significant Creatine Kinase Elevation with Statins
Stolcpart, R. S., Olson, K. L., Delate, T., Rasmussen, J. R., Rehring, T. F., & Merenich, J. A. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/11536130-000000000-00000 · Cited by 16
Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia
Bays, H. E., Sapre, A., Taggart, W. V., Ji, L., Capece, R., & Tershakovec, A. M. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802365094 · Cited by 16
Self-citation
Statins and peripheral neuropathy in diabetic and non-diabetic cases: a systematic review
Daliri, M., Johnston, T. P., & Sahebkar, A. (2023) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgac104 · Cited by 15
Management of intracerebral hemorrhage – use of statins
Kiser, T. H., Matre, E. T. V., & Sherman, D. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s75399 · Cited by 15
Clinical features related to statin‐associated muscle symptoms
Ochs‐Balcom, H. M., Nguyen, L. M., Ma, C., Isackson, P. J., Luzum, J. A., Kitzmiller, J. P., Tarnopolsky, M. A., Weisman, M. H., Christopher‐Stine, L., Peltier, W., et al. (2018) · Muscle & Nerve · doi:10.1002/mus.26397 · Cited by 17
Managing statin-induced muscle toxicity in a lipid clinic
Blaier, O., Lishner, M., & Elis, A. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01254.x · Cited by 14
Interpretation of creatine kinase and aldolase for statin-induced myopathy: Reliance on serial testing based on biological variation
Wu, A. H. B., Smith, A. M., & Wians, F. H. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.09.023 · Cited by 14
Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients
Becker, D. J., & Gordon, R. Y. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-2-201001190-00026 · Cited by 13
Microsomal Transfer Protein Inhibitors, New Approach for Treatment of Familial Hypercholesterolemia, Review of the Literature, Original Findings, and Clinical Significance
Kolovou, G. D., Vasiliadis, I. K., Gontoras, N., Kolovou, V., & Hatzigeorgiou, G. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12105 · Cited by 13
The effect of two novel cholesterol-lowering agents, disodium ascorbyl phytostanol phosphate (DAPP) and nanostructured aluminosilicate (NSAS) on the expression and activity of P-glycoprotein within Caco-2 cells
Sachs‐Barrable, K., Darlington, J. W., & Wasan, K. M. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-153 · Cited by 13
Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©
Jacobson, T. A., Edelman, S. V., Galipeau, N., Shields, A. L., Mallya, U. G., Koren, A., & Davidson, M. H. (2016) · Patient · doi:10.1007/s40271-016-0211-y · Cited by 13
Cholesterol lowering for secondary prevention: what statin dose should we use?
Josan, K., & McAlister, F. A. (2007) · PubMed Central · Cited by 13
Interacciones medicamentosas en pacientes infectados con el VIH: aproximación para establecer y evaluar su relevancia clínica
Amariles, P., Giraldo, N. A., & Faus, M. J. (2007) · Farmacia Hospitalaria · doi:10.1016/s1130-6343(07)75392-8 · Cited by 13
Statin Associated Hepatic Adverse Effects: A Retrospective Review from a Regional Hospital in Sultanate of Oman
José, J., Al-Tamimi, F. A. A., Helal, M. M., Jimmy, B., & Al-Riyami, Q. A. (2014) · Oman Medical Journal · doi:10.5001/omj.2014.93 · Cited by 12
Repeatedly heated mix vegetable oils-induced atherosclerosis and effects of Murraya koenigii
Gul, A., Siddiq, A., Hussain, K., Hussain, A. S., & Naz, Z. (2020) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-020-03012-4 · Cited by 12
Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease
Shek, A. B., Kurbanov, R. D., Abdullaeva, G. J., Nagay, A. V., Hoshimov, S. U., Nizamov, U. I., Васиковна, З. А., & Alieva, R. B. (2017) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2017.70597 · Cited by 11
Rosuvastatin-Induced Acute Interstitial Nephritis
Londrino, F., Zattera, T., Falqui, V., Corbani, V., Cavallini, M., Stefanini, T., Chiappini, N., Ardini, M., Martina, V., & Rombolà, G. (2013) · Case Reports in Nephrology and Dialysis · doi:10.1159/000353175 · Cited by 11
Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia
Li, J., Wang, X., Zhang, Z., Zou, J., Chen, Y., Wang, X., & Wu, J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.858619 · Cited by 11
The effect of statins on performance in the Morris water maze in guinea pig
Maggo, S. D. S., Clark, D. W. J., & Ashton, J. C. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.11.006 · Cited by 11
Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin
Engel, S. S., Anderson, K. M., Hanson, Musliner, & Steinberg, H. O. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s44330 · Cited by 11
Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: A pooled analysis of thirty clinical trials
WINKLER, K., ABLETHAUSER, C., Gimpelewicz, C. R., Bortolini, M., & Isaacsohn, J. L. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.026 · Cited by 11
MOLECULAR BACKGROUNDS OF INDIVIDUALISED PHARMACOTHERAPY
Neamțu, M. (2020) · FARMACIA · doi:10.31925/farmacia.2020.3.4 · Cited by 5
That Myalgia of Yours Is Not From Statin Intolerance
Toth, P. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.025 · Cited by 10
Rosuvastatin in Elderly Patients
Davidson, M. H. (2007) · Drugs & Aging · doi:10.2165/00002512-200724110-00005 · Cited by 10
Statins
McKenney, J. M., Ganz, P., Wiggins, B. S., & Saseen, J. J. (2009) · Elsevier eBooks · doi:10.1016/b978-141605469-6.50026-3 · Cited by 10
Combination therapy of dyslipidemia
Goldberg, A. C. (2007) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-007-0020-7 · Cited by 9
The association between statins exposure and peripheral neuropathy risk: A meta‐analysis
Wang, M., Li, M., & Xie, Y. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13393 · Cited by 9
Statins- A review of benefits and risks
O’Sullivan, S. (2007) · Trinity Student Medical Journal · Cited by 8
The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia
Шуев, Г. Н., Sychev, D. A., Chertovskih, J. V., Grachev, A., Syrkova, O., & Максимова, Н. Р. (2016) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s99634 · Cited by 8
Prior Cardiovascular Treatments—A Key Characteristic in Determining Medication Adherence After an Acute Myocardial Infarction
Campain, A. E., Hockham, C., Sukkar, L., Rogers, K. D., Chow, C. K., Lung, T. W.-C., Jun, M., Pollock, C. A., Cass, A., SULLIVAN, D. R., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.834898 · Cited by 7
The main side effects of statins in clinical practice
Chaulin, A. M. (2022) · Journal of clinical practice · doi:10.17816/clinpract108076 · Cited by 7
Evaluation of Medication Compliance for Secondary Prevention of Acute Coronary Syndrome
Gill, D., Feldman, E. A., & Liu, K. (2017) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2017.11930208 · Cited by 7
Elevated Liver Enzymes: Emergency Department–Focused Management
Sulava, E., Bergin, S. W., Long, B., & Koyfman, A. (2016) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2016.10.016 · Cited by 7
Simvastatin Impairs Glucose Homeostasis in Mice Depending on PGC-1α Skeletal Muscle Expression
Panajatovic, M. V., Singh, F., Krähenbühl, S., & Bouitbir, J. (2020) · Biomedicines · doi:10.3390/biomedicines8090351 · Cited by 7
Letter to the editor
JOY, T. R., & Hegele, R. A. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70133-3 · Cited by 6
Is there a role for earlier use of combination therapy?
Revankar, S., Park, J. K., Satish, P., & Agarwala, A. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100639 · Cited by 6
Exclusively plant, whole-food diet for polypharmacy due to persistent atrial fibrillation, ischaemic cardiomyopathy, hyperlipidaemia and hypertension in an octogenarian
Beauchesne, A. B., Goldhamer, A. C., & Myers, T. R. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-227059 · Cited by 6
Latest Updates on Lipid Management
Egom, E. E. A., Pharithi, R. B., Hesse, S., Starr, N., Armstrong, R. L., Sulaiman, H. M., Gazdíková, K., Mozos, I. M., Čaprnda, M., Kubatka, P., et al. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00306-8 · Cited by 5
Critical Appraisal of Physiochemical Characteristics of Statins and Drug Delivery Systems for Improving Their Bioavailability
Abd-Elghany, A. E., El-Garhy, O. H., & elbarbary, H. (2022) · Journal of advanced Biomedical and Pharmaceutical Sciences · doi:10.21608/jabps.2022.160285.1164 · Cited by 6
Statin induced myopathy presenting as mechanical musculoskeletal pain observed in two chiropractic patients.
Rodine, R. J., Tibbles, A. C., Kim, P. S., & Alikhan, N. (2010) · Europe PMC (PubMed Central) · Cited by 6
Potential drug interactions with statins: Estonian register-based study
Gavronski, M., Volmer, D., Hartikainen, S. A., & Zharkovsky, A. (2015) · Open Medicine · doi:10.1515/med-2015-0038 · Cited by 6
Neue Aspekte der perioperativen Statintherapie
Butte, N., Böttiger, B. W., Liakopoulos, O. J., & Teschendorf, P. (2010) · Der Anaesthesist · doi:10.1007/s00101-010-1725-7 · Cited by 6
Statins and Hepatotoxicity
Dourakis, S. P. (2007) · Annals of Gastroenterology · Cited by 6
Statins in Chronic Liver Disease: Review of the Literature and Future Role
Pham, N., & Benhammou, J. N. (2024) · Seminars in Liver Disease · doi:10.1055/a-2319-0694 · Cited by 5
Incidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers
Choi, W. J., Kim, G., Park, J., Jang, S., Jung, W. J., Shim, J., Park, Y., Choi, G. H., Kim, J., Jeong, S., et al. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e255 · Cited by 6
Addressing Lipid Treatment Targets Beyond Cholesterol: A Role for Prescription Omega-3 Fatty Acid Therapy
Dall, T., & Bays, H. E. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e31819b08f7 · Cited by 5
Self-citation
Benefit/Risk Ratio of Statins in Primary Prevention
Mm, R. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100256 · Cited by 5
[Intensive cholesterol drug lowering: how to be sure about their safety].
da Silva, P. M. (2010) · PubMed · Cited by 5
No additional cholesterol-lowering effect observed in the combined treatment of red yeast rice and Lactobacillus casei in hyperlipidemic patients: A double-blind randomized controlled clinical trial
Lee, C., Yu, M., Perng, W.-T., Lin, C.-C., Lee, M., Chang, Y.-L., Lai, Y.-Y., Lee, Y., Kuan, Y., Wei, J. C., et al. (2016) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-016-2530-1 · Cited by 5
Difference in occurrence of muscle-related adverse effects of statins among male and female geriatric patients: A cross-sectional observational study
Gupta, Y., Singh, H., Chakrawarti, A., Guruprasad, P., & Singh, H. (2016) · Nigerian Postgraduate Medical Journal · doi:10.4103/1117-1936.196262 · Cited by 5
A Genomic DNA Reporter Screen Identifies Squalene Synthase Inhibitors That Act Cooperatively with Statins to Upregulate the Low-Density Lipoprotein Receptor
Kerr, A. G., Tam, L. C. S., Hale, A., Cioroch, M., Douglas, G., Agkatsev, S., Hibbitt, O., Mason, J. S., Holt‐Martyn, J. P., Bataille, C. J. R., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239574 · Cited by 5
Clinical Relevance of Drug Interactions in HIV-Infected Patients Receiving Antiretroviral Therapy
Amariles, P., Giraldo, N. A., & Jose, M. (2011) · InTech eBooks · doi:10.5772/19408 · Cited by 4
Association between variants of COQ2 and TNF-α genes and statin-induced toxicities in Bangladeshi hyperlipidemic patients
Chowdhury, F. A., Baker, S. M. E. A., Islam, M. S., Nahid, N. A., Al-Mamun, M. M. A., Islam, M. R., Apu, M. N. H., Nahar, Z., Ahmed, M. U., & Hasnat, A. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00677-x · Cited by 4
Beneficial effects of combined administration of sodium molybdate with atorvastatin in hyperlipidemic hamsters.
Ahmed, A. A. E. (2009) · PubMed · Cited by 4
Atorvastatin and lovastatin, but not pravastatin, increased cellular complex formation between PCSK9 and the LDL receptor in human hepatocyte-like C3A cells
Melendez, Q. M., Wooten, C. J., & Lopez, D. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.08.026 · Cited by 4
Abordagem aos Doentes com Intolerância às Estatinas: Revisão Baseada na Evidência
Almeida, J. T., Esteves, A. L., Martins, F., & Palma, I. (2020) · Acta Médica Portuguesa · doi:10.20344/amp.10376 · Cited by 4
Pharmacogenetics of the response to statins
Voora, D., & Ginsburg, G. S. (2009) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-009-0064-1 · Cited by 4

Authors: Bays, H.
Affiliations: Louisville Metabolic and Atherosclerosis Research Center (US)
Corresponding author: Bays, Harold
ORCID: Bays, Harold
Venue: The American Journal of Cardiology
Publisher: Elsevier BV
Published: 2006-04
Volume: 97
Issue: 8
Pages: S6-S26
ISSN: 0002-9149 (ISSN-L)
DOI: 10.1016/j.amjcard.2005.12.006
OpenAlex: W2011527537
Cited by: 264
References: 205
Citations by year: 2026: 3 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 7 · 2021: 6 · 2020: 10 · 2019: 10 · 2018: 12 · 2017: 19 · 2016: 17 · 2015: 11 · 2014: 17 · 2013: 15 · 2012: 12
FWCI: 5.20
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The American Journal of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords: statins, drug safety, adverse drug reactions, rhabdomyolysis, elevated liver enzymes, renal function, cognitive effects, lipid-lowering therapy, coronary artery disease, all-cause mortality
MeSH terms: Hypolipidemic Agents, Dementia, Dose-Response Relationship, Drug, Drug Therapy, Combination, Humans, Kidney Diseases, Liver, Muscular Diseases, Peripheral Nervous System Diseases, Proteinuria, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine, Stroke, Chemical and Drug Induced Liver Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Statin Safety: An Overview and Assessment of the Data—2005

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks